双醋瑞因对血糖控制不佳的2型糖尿病患者的疗效与安全性:一项随机对照试验
这项随机双盲安慰剂对照试验纳入84例HbA1c 7.5–9.5%(58–80 mmol/mol)的2型糖尿病患者,随机接受48周安慰剂(n=41)或双醋瑞因100 mg/日(n=43)治疗。意向性分析显示双醋瑞因较安慰剂降低HbA1c 0.35%(3.8 mmol/mol;P=0.038),效应峰值在第24周,至第48周衰减至无显著差异。腹泻发生率65%,16%因腹泻中断治疗。
要点
- 双醋瑞因100 mg/日治疗48周,意向性分析中HbA1c较安慰剂降低0.35%(P=0.038)。
- 降糖效应峰值在第24周(-0.61%,P=0.014),至第48周衰减至无显著差异。
- 腹泻发生率65%,16%的患者因腹泻中断治疗;轻度低血糖事件组间相当。
核心结论
- 双醋瑞因降低平均HbA1c水平,效应峰值在第24周,药物耐受性良好,可能作为2型糖尿病患者的辅助治疗,尤其是合并骨关节炎者。
研究设计与样本
- 随机、双盲、安慰剂对照试验,纳入84例HbA1c在7.5–9.5%(58–80 mmol/mol)之间的2型糖尿病患者,随机接受48周安慰剂(n=41)或双醋瑞因100 mg/日(n=43)治疗。
- 主要结局为治疗期间平均HbA1c变化的差异;采用调整年龄、性别、糖尿病病程及各项基线值的重复测量一般线性回归估计平均变化差异。
- 同时进行意向性分析(ITT)和符合方案分析(排除10例中断治疗的患者)。
主要发现
- 意向性分析中,双醋瑞因较安慰剂降低HbA1c 0.35%(3.8 mmol/mol;P=0.038);符合方案分析中降低0.41%(4.5 mmol/mol;P=0.023)。
- 效应峰值出现在治疗第24周:意向性分析中降低0.61%(6.7 mmol/mol;P=0.014),符合方案分析中降低0.78%(8.5 mmol/mol;P=0.005)。
- 至第48周,HbA1c差异衰减至无统计学显著差异。
- 其他疗效和安全性指标中未观察到双醋瑞因的显著效应。
- 双醋瑞因组65%的患者发生腹泻,16%因此中断治疗;双醋瑞因组7例减少胰岛素剂量,安慰剂组10例增加胰岛素剂量,但轻度低血糖事件两组相当。
临床怎么用
- 作者认为双醋瑞因可能作为2型糖尿病患者的辅助治疗,尤其是合并骨关节炎者。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess, in a randomized, double-blind, and placebo-controlled trial, the efficacy and safety of diacerein, an immune modulator anti-inflammatory drug, in improving glycemic control of patients with type 2 diabetes. RESEARCH DESIGN AND METHODS: Eighty-four patients with HbA1c between 7.5 and 9.5% (58-80 mmol/mol) were randomized to 48-week treatment with placebo (n = 41) or diacerein 100 mg/day (n = 43). The primary outcome was the difference in mean HbA1c changes during treatment. Secondary outcomes were other efficacy and safety measurements. A general linear regression with repeated measures, adjusted for age, sex, diabetes duration, and each baseline value, was used to estimate differences in mean changes. Both intention-to-treat (ITT) analysis and per-protocol analysis (excluding 10 patients who interrupted treatment) were performed. RESULTS: Diacerein reduced HbA1c compared with placebo by 0.35% (3.8 mmol/mol; P = 0.038) in the ITT analysis and by 0.41% (4.5 mmol/mol; P = 0.023) in the per-protocol analysis. The peak of effect occurred at the 24th week of treatment (-0.61% [6.7 mmol/mol; P = 0.014] and -0.78% [8.5 mmol/mol; P = 0.005], respectively), but it attenuated toward nonsignificant differences at the 48th week. No significant effect of diacerein was observed in other efficacy and safety measures. Diarrhea occurred in 65% of patients receiving diacerein and caused treatment interruption in 16%. Seven patients in the diacerein group reduced insulin dosage, whereas 10 in the placebo group increased it; however, mild hypoglycemic events were equally observed. CONCLUSIONS: Diacerein reduced mean HbA1c levels, with peak of effect at the 24th week of treatment. The drug was well tolerated and may be indicated as adjunct treatment in patients with type 2 diabetes, particularly in those with osteoarthritis.
引用
- Cardoso CRL, Leite NC, Carlos FO, et al. Efficacy and Safety of Diacerein in Patients With Inadequately Controlled Type 2 Diabetes: A Randomized Controlled Trial. Diabetes Care. 2017. PMID: 28818994. doi:10.2337/dc17-0374
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。